Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ·Healthcare·Biotechnology
$26.87
+8.31%
Mkt Cap $2.26B
Analyst Ratings
No recent rating data.
Price Target (42 analysts)
$51.50
Range $34.00 – $67.00
Implied Upside
+91.7%
Consensus $51.50 vs current $26.87